Bionyra
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immunological and inflammatory diseases. Bionyra’s best-in-class mono and multispecific antibodies target novel immune pathways, enabling deeper and more durable disease control, with an initial focus on atopic dermatitis and inflammatory bowel disease. Seed financed by Sofinnova Partners, Bionyra was co-founded by Sofinnova Partners and Frédéric Marrache, MD, PhD, MBA, a former Sanofi R&D executive with deep immunology expertise.
Sector
Biopharmaceuticals
Strategies
Status
Live
Website
Bionyra.com
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.